← All trials
NCT05491304
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2022
- Primary completion
- Dec 31, 2024
- Completion date
- Dec 31, 2025
- First posted
- Aug 8, 2022
- Last posted
- Oct 6, 2022
- Enrollment
- 400
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Zhejiang UniversityLead sponsor
- Huazhong University of Science and TechnologyCollaborator
- Central South UniversityCollaborator
- Central South UniversityCollaborator
- Anhui Medical UniversityCollaborator
- Nanjing Medical UniversityCollaborator
- Qingdao UniversityCollaborator
- Sichuan UniversityCollaborator
- Fudan UniversityCollaborator
- Fujian Medical UniversityCollaborator
- Wenzhou Medical UniversityCollaborator
- Soochow UniversityCollaborator
- Zhejiang UniversityOverall official - principal investigator
- Zhejiang UniversityReponsible party - principal investigator
- Shandong UniversityCollaborator
- Jiao Tong UniversityCollaborator
- Jiao Tong UniversityCollaborator
- Jiao Tong UniversityCollaborator
- Sun Yat-Sen UniversityCollaborator
- Zunyi Medical CollegeCollaborator
- Shenzhen UniversityCollaborator
- Wuhan Children's HospitalCollaborator
- Chinese Academy of Medical SciencesCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.